[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY2434B1 - Antifungal compositions with improved bioavailability. - Google Patents

Antifungal compositions with improved bioavailability.

Info

Publication number
CY2434B1
CY2434B1 CY0400023A CY0400023A CY2434B1 CY 2434 B1 CY2434 B1 CY 2434B1 CY 0400023 A CY0400023 A CY 0400023A CY 0400023 A CY0400023 A CY 0400023A CY 2434 B1 CY2434 B1 CY 2434B1
Authority
CY
Cyprus
Prior art keywords
improved bioavailability
antifungal compositions
antifungal
compositions
bioavailability
Prior art date
Application number
CY0400023A
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Geert Verreck
Dany Thone
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2434(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY2434B1 publication Critical patent/CY2434B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0400023A 1996-05-20 2004-03-29 Antifungal compositions with improved bioavailability. CY2434B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07

Publications (1)

Publication Number Publication Date
CY2434B1 true CY2434B1 (en) 2004-11-12

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0400023A CY2434B1 (en) 1996-05-20 2004-03-29 Antifungal compositions with improved bioavailability.

Country Status (34)

Country Link
US (4) US6509038B2 (xx)
EP (1) EP0904060B1 (xx)
JP (1) JP3391801B2 (xx)
KR (1) KR19990044257A (xx)
CN (1) CN1165291C (xx)
AR (1) AR007195A1 (xx)
AT (1) ATE255883T1 (xx)
AU (1) AU722101B2 (xx)
BG (1) BG64368B1 (xx)
BR (1) BR9706897B1 (xx)
CA (1) CA2240161C (xx)
CY (1) CY2434B1 (xx)
CZ (1) CZ293841B6 (xx)
DE (1) DE69726729T2 (xx)
DK (1) DK0904060T3 (xx)
EA (1) EA001219B1 (xx)
EE (1) EE03902B1 (xx)
ES (1) ES2212810T3 (xx)
HK (1) HK1018002A1 (xx)
HR (1) HRP970270B1 (xx)
HU (1) HU227745B1 (xx)
ID (1) ID16926A (xx)
IL (1) IL124935A (xx)
MX (1) MX9805418A (xx)
MY (1) MY123827A (xx)
NO (1) NO320495B1 (xx)
NZ (1) NZ330739A (xx)
PL (1) PL188566B1 (xx)
PT (1) PT904060E (xx)
SI (1) SI0904060T1 (xx)
SK (1) SK284145B6 (xx)
TR (1) TR199801225T2 (xx)
TW (1) TW460282B (xx)
WO (1) WO1997044014A1 (xx)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
AU1511399A (en) * 1997-12-31 1999-07-19 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
CA2362728C (en) 1999-03-24 2009-06-23 Fmc Corporation Improved aqueous solubility pharmaceutical formulations
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
ES2398643T3 (es) * 1999-12-23 2013-03-20 Mayne Pharma International Pty Ltd. Composiciones farmacéuticas mejoradas para fármacos escasamente solubles
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
SK287582B6 (sk) 2001-02-14 2011-03-04 Tibotec Pharmaceuticals Ltd. 2-(Substituovaná amino)benztiazolsulfonamidová zlúčenina, spôsob jej prípravy, použitie a farmaceutická zmes s jej obsahom
IL158092A0 (en) 2001-04-09 2004-03-28 Tibotec Pharm Ltd Broadspectrum 2- (substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
JP4467889B2 (ja) 2001-05-11 2010-05-26 テイボテク・フアーマシユーチカルズ・リミテツド 広範囲２−アミノ−ベンズオキサゾールスルホンアミドｈｉｖプロテアーゼ阻害剤
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
WO2003011254A1 (en) * 2001-07-31 2003-02-13 Capricorn Pharma Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
MY138657A (en) 2001-12-21 2009-07-31 Tibotec Pharm Ltd broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
IL161134A0 (en) * 2002-02-28 2004-08-31 Japan Tobacco Inc Ester compound and medical use thereof
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
US7462636B2 (en) 2002-05-17 2008-12-09 Tibotec Pharmaceuticals Ltd Broadspectrum substituted benzisoxazole sulfonamide HIV protease inhibitors
NZ536975A (en) * 2002-07-04 2006-10-27 Janssen Pharmaceutica Nv Solid dispersions of a poorly soluble bioactive compound comprising two different polymer matrixes
CN1688586B (zh) 2002-08-14 2012-05-09 泰博特克药品有限公司 取代的羟吲哚磺酰胺类广谱hiv蛋白酶抑制剂
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
DK1438961T4 (da) * 2003-01-14 2014-11-17 Acino Pharma Ag Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
US8486447B2 (en) * 2003-02-03 2013-07-16 Novartis Ag Pharmaceutical formulation
US20060172010A1 (en) * 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
UA84020C2 (ru) 2003-09-11 2008-09-10 Тиботек Фармасьютикелз Лтд. Ингибитор проникновения вируса вил
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
JP2007526341A (ja) * 2004-03-03 2007-09-13 スフェリックス， インコーポレイテッド 疎水性薬物のためのポリマー薬物送達システム
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
AU2005244121B2 (en) 2004-05-07 2012-01-19 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
AR049637A1 (es) 2004-05-17 2006-08-23 Tibotec Pharm Ltd 1-fenil-1,5-dihidro-pirido[3,2-b]indol-2-onas sustituidas en las posiciones 6, 7, 8, 9
CN1953983B (zh) 2004-05-17 2010-05-26 泰博特克药品有限公司 1-杂环基-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
JP4879889B2 (ja) 2004-05-17 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド ４−置換−１，５−ジヒドロ−ピリド［３，２−ｂ］インドール−２−オン
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) * 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
US8486456B2 (en) 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
WO2007017249A1 (en) 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
EP1919480B1 (en) * 2005-08-22 2013-01-16 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
CA2646090A1 (en) 2006-04-03 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
PL2034975T3 (pl) 2006-06-19 2012-09-28 Alpharma Pharmaceuticals Llc Kompozycje farmaceutyczne
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CA2990445C (en) * 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
PL2224914T3 (pl) 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
EP2520285A1 (en) 2007-09-27 2012-11-07 Wockhardt Limited Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
CA2707161C (en) 2007-11-28 2016-08-16 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome p450 2d6
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
CN101951891A (zh) * 2008-01-11 2011-01-19 希普拉有限公司 固态药物剂型
EP2257160B1 (en) 2008-02-21 2017-07-05 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2262484B1 (en) 2008-03-11 2013-01-23 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
SG10201403986UA (en) * 2008-04-15 2014-10-30 Merck Sharp & Dohme High Density Compositions Containing Posaconazole And Formulations Comprising The Same
EA013132B1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
WO2011074961A1 (en) 2009-12-18 2011-06-23 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
BR112013008737A2 (pt) * 2010-10-14 2015-09-01 Abbott Gmbh & Co Kg Formulação de dispersão sólida de curcuminóide
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
IN2014CN00827A (xx) * 2011-08-16 2015-04-03 Merck Sharp & Dohme
CN103827105B (zh) 2011-08-18 2016-08-17 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
WO2014014752A1 (en) * 2012-07-17 2014-01-23 Dow Global Technologies Llc Solid dispersion comprising a highly substituted hydroxyalkyl methylcellulose
CA2891502A1 (en) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
CN104936589A (zh) 2013-01-22 2015-09-23 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
WO2015108768A1 (en) 2014-01-16 2015-07-23 Dow Global Technologies Llc Support materials for 3d printing
EP3307839B1 (en) * 2015-06-09 2019-02-27 Dow Global Technologies LLC Support materials for 3d printing
EP3454847A4 (en) * 2016-05-09 2019-12-18 Dispersol Technologies, LLC IMPROVED DRUG FORMULATIONS
EP3675832A1 (en) 2017-09-01 2020-07-08 Jordan Sweden Medical and Sterilization Company Fast self dispersible dosage forms of deferasirox
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
KR20220054311A (ko) * 2019-08-28 2022-05-02 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 선형 폴리(아크릴산) 중합체를 사용한 약물-중합체 무정형 고체 분산체
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
JP2024530727A (ja) 2021-08-25 2024-08-23 ビーエーエスエフ ソシエタス・ヨーロピア 直接打錠補助組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
ATE5852T1 (de) 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Ｎｂ―８１８の易吸収性製剤
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
ATE159426T1 (de) * 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
EP0631578B1 (en) * 1992-03-18 2001-05-23 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) * 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
US20010007678A1 (en) 2001-07-12
AU2956297A (en) 1997-12-09
US20030082239A1 (en) 2003-05-01
DE69726729T2 (de) 2004-12-02
EA001219B1 (ru) 2000-12-25
AU722101B2 (en) 2000-07-20
BG102532A (en) 1999-02-26
EA199800571A1 (ru) 1998-12-24
CA2240161A1 (en) 1997-11-27
DK0904060T3 (da) 2004-04-13
HUP9901620A2 (hu) 1999-10-28
IL124935A0 (en) 1999-01-26
CZ188598A3 (cs) 1998-11-11
ID16926A (id) 1997-11-20
EE03902B1 (et) 2002-12-16
BG64368B1 (bg) 2004-12-30
EP0904060B1 (en) 2003-12-10
US20060263436A1 (en) 2006-11-23
EE9800304A (et) 1999-02-15
ES2212810T3 (es) 2004-08-01
KR19990044257A (ko) 1999-06-25
IL124935A (en) 2001-06-14
WO1997044014A1 (en) 1997-11-27
US7081255B2 (en) 2006-07-25
JPH11509238A (ja) 1999-08-17
SK284145B6 (sk) 2004-10-05
MX9805418A (es) 1998-10-31
US9642806B2 (en) 2017-05-09
DE69726729D1 (de) 2004-01-22
NO982599D0 (no) 1998-06-05
US8591948B2 (en) 2013-11-26
TR199801225T2 (xx) 1998-11-23
BR9706897B1 (pt) 2010-09-21
NZ330739A (en) 1999-06-29
US20140134244A1 (en) 2014-05-15
HRP970270A2 (en) 1998-04-30
ATE255883T1 (de) 2003-12-15
MY123827A (en) 2006-06-30
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
CZ293841B6 (cs) 2004-08-18
SI0904060T1 (en) 2004-04-30
CA2240161C (en) 2005-05-24
HRP970270B1 (en) 2005-02-28
AR007195A1 (es) 1999-10-13
NO982599L (no) 1998-11-19
PL330931A1 (en) 1999-06-07
BR9706897A (pt) 1999-08-31
CN1165291C (zh) 2004-09-08
NO320495B1 (no) 2005-12-12
EP0904060A1 (en) 1999-03-31
HK1018002A1 (en) 1999-12-10
US6509038B2 (en) 2003-01-21
HUP9901620A3 (en) 2000-03-28
TW460282B (en) 2001-10-21
JP3391801B2 (ja) 2003-03-31
SK84898A3 (en) 1999-03-12
HU227745B1 (en) 2012-02-28
CN1209740A (zh) 1999-03-03

Similar Documents

Publication Publication Date Title
CY2434B1 (en) Antifungal compositions with improved bioavailability.
ZA978579B (en) Herbicidal composition.
ZA987489B (en) Fungicidal 2-methoxybenzophenones.
ZA978178B (en) Composition.
ZA975735B (en) Pesticidal compositions.
ZA976119B (en) Pesticidal compositions.
ZA984849B (en) Compositions.
ZA9711092B (en) Novel compounds.
ZA975261B (en) Composition.
DZ2205A1 (fr) Compositions antifongiques.
ZA973629B (en) Pesticidal composition.
ZA973344B (en) Antifungal compositions.
ZA977207B (en) Amino-lipopeptide antifungal agents.
ZA9711567B (en) Compounds.
ZA987055B (en) Substituted 4-benzoylpyrazoles.
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA974428B (en) Antifungal composition with enhanced bioavailability.
ZA9811502B (en) Novel composition.
ZA975861B (en) Bromotiacumicin compounds.
IL123715A0 (en) Antifungal compositions
ZA973045B (en) Pesticidal compositions.
ZA971638B (en) Microbicidal composition.
ZA979898B (en) Organic compositions.
ZA987B (en) Substituted 4-benzoylpyrazoles.
ZA972516B (en) Rodenticide.